Kamada Ltd. (KMDA)

Market Cap	464.48M +15.5%
Revenue (ttm)	181.68M +8.6%
Net Income	20.37M +26.8%
EPS	0.35 +24.4%
Shares Out	59.03M
PE Ratio	22.81
Forward PE	16.92
Dividend	$0.25 (3.19%)
Ex-Dividend Date	Mar 23, 2026

Volume	72,237
Open	7.86
Previous Close	7.82
Day's Range	7.72 - 7.89
52-Week Range	6.50 - 9.35
Beta	0.20
Analysts	Strong Buy
Price Target	13.00 (+66.03%)
Earnings Date	May 13, 2026

About KMDA

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM f...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1990
• Employees: 462
• Stock Exchange: NASDAQ
• Ticker Symbol: KMDA
• Website: https://www.kamada.com

Financial Performance

In 2025, Kamada's revenue was $180.46 million, an increase of 12.12% compared to the previous year's $160.95 million. Earnings were $20.20 million, an increase of 39.66%.

Analyst Summary

According to 3 analysts, the average rating for KMDA stock is "Strong Buy." The 12-month stock price target is $13.0, which is an increase of 66.03% from the latest price.

Price Target

$13.0

(66.03% upside)

Analyst Consensus: Strong Buy